Kidney function can substantially change the handling of some antiseizure medicines. Chronic kidney disease, acute kidney injury and dialysis can therefore affect dose selection, drug concentrations and toxicity risk.
Not every antiseizure medicine depends on the kidneys equally
Some medicines are cleared predominantly through the kidneys, while others rely more heavily on hepatic metabolism.
The degree of renal dependence determines whether dose reduction or longer dosing intervals may be needed as kidney function declines.
Why estimated kidney function matters
Drug dosing often uses creatinine-based estimates of renal function, but these estimates have limitations in people with very low muscle mass, frailty or rapidly changing kidney function.
A medicine dose should therefore be interpreted alongside the clinical picture rather than from one laboratory number alone.
Dialysis can remove some medicines
Haemodialysis can substantially remove certain antiseizure drugs from the bloodstream.
For some medicines, supplemental dosing after dialysis may be required; others are minimally dialysed. The correct approach is drug-specific.
Toxicity can resemble neurological deterioration
Accumulation can produce sleepiness, confusion, ataxia, dizziness, myoclonus or other neurological symptoms.
In a person with epilepsy and renal failure, these symptoms should not automatically be assumed to represent worsening seizures.
Protein binding can change
Kidney failure can alter protein binding and the relationship between total and pharmacologically active free drug concentrations.
This can be particularly important for highly protein-bound medicines such as phenytoin.
Acute kidney injury is different from stable chronic disease
A dose that was appropriate during stable chronic kidney disease may become excessive when renal function suddenly worsens.
Medication review should therefore accompany significant acute changes in kidney function.
Modern drugs still require individual review
Recent pharmacokinetic reviews show substantial differences between newer antiseizure medicines in renal impairment and dialysis.
Prescribing information also differs between regulatory regions, so local product information and specialist pharmacy advice remain important.
Related reading
Sources and further reading
- Antiseizure medications in renal failure undergoing dialysis — 2025 review
- Pharmacokinetics, safety and dosing of newer ASMs in renal or hepatic impairment — 2026
Evidence checked: September 2026.